Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature. - Test2 - elhamkhani - TriplyDB

Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature.

Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature.

http://www.wikidata.org/entity/Q37294341

about

Women and Chest Pain: Recognizing the Different Faces of Angina in the Emergency Department Chronic antihypertensive treatment improves pulse pressure but not large artery mechanics in a mouse model of congenital vascular stiffness Increased vascular smooth muscle cell stiffness: a novel mechanism for aortic stiffness in hypertension Social jetlag and metabolic control in non-communicable chronic diseases: a study addressing different obesity statuses.

P2860

Q26746172-1DD67B27-5F32-410C-B17F-FC52420A6176 Q36114288-8FF26B5D-3DD8-4809-8613-C5699333A70A Q37342081-5E52514D-BBF2-413F-863C-B69FD7C6E924 Q41123367-C22B72E2-E230-45AE-B884-4D92DB0A2D7A

P2860

Circulatory therapeutics: use of antihypertensive agents and their effects on the vasculature.

http://www.wikidata.org/entity/Q37294341

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 19 March 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Circulatory therapeutics: use ...... ir effects on the vasculature.

@en

Circulatory therapeutics: use ...... ir effects on the vasculature.

@nl

type

label

Circulatory therapeutics: use ...... ir effects on the vasculature.

@en

Circulatory therapeutics: use ...... ir effects on the vasculature.

@nl

prefLabel

Circulatory therapeutics: use ...... ir effects on the vasculature.

@en

Circulatory therapeutics: use ...... ir effects on the vasculature.

@nl

P1433

Q37294341-641BA36F-70DA-48DB-8DED-39CFEA65F8B7

P1476

Q37294341-01D0BB2A-F4A5-41DA-BDC3-7C6771305083

P2093

Q37294341-24B35085-B474-47E6-8781-F3A5B26E6EF0

P2860

Q37294341-022A672D-10E7-4CCB-9CA4-55099C382E54

Q37294341-03FE2C3D-A8DF-44BC-8213-5151907C90DA

Q37294341-04ECB579-0539-42C0-9698-4BCF793C8FD4

Q37294341-0B12A328-DBE6-4294-811F-A1DA75D03BE8

Q37294341-0BF25C8B-F7B6-4F1E-8C25-B13A73059BD7

Q37294341-1D702F30-77A1-45C4-9122-FA29C9302E5D

Q37294341-203C087B-10C3-4277-A535-29B86227552C

Q37294341-250AC2E9-AEC7-4D9C-8BF4-742A81BC1915

Q37294341-259EDEDE-7042-48A4-979D-D65372DB61AA

Q37294341-2778EE95-F01A-435A-9FED-D44C525FAE3E

P304

Q37294341-301B29F8-62C1-4E5D-8BF3-78D9D2BA6F06

P31

Q37294341-6043C218-A90D-4256-B70F-624773542AD4

Q37294341-70D7B202-1BE9-4258-94B4-C28B94143DD7

P356

Q37294341-A07FB9EB-C6CB-4930-BA66-F410791273C6

P433

Q37294341-D705C8CD-4392-46AF-9418-0C78CC81B904

P478

Q37294341-C672F8F2-9930-4560-9BB9-2C9FAF5B8457

P577

Q37294341-9D137CAA-695E-463F-8C25-779A3F557399

Q37294341-C87F1575-E9F5-4B27-9809-CB91D957ACF1

P5875

Q37294341-1D86F0B9-46E0-4DBF-985A-DC061930AAF7

P698

Q37294341-74455D10-81AD-4BFA-95CC-DC15D49541D0

P921

Q37294341-3A532025-EEE3-471F-B66B-1C0C2864F318

P932

Q37294341-AD7C4702-7607-4820-828A-6EBD8BD41774

P356

J.1582-4934.2010.01056.X

P1433

Journal of Cellular and Molecular Medicine

P1476

Circulatory therapeutics: use ...... ir effects on the vasculature.

@en

P2093

Ernesto L Schiffrin

http://www.w3.org/2001/XMLSchema#string

P2860

Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack

Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group

The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

P304

1018-1029

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1582-4934.2010.01056.X

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2010-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42608584

http://www.w3.org/2001/XMLSchema#string

P698

20345850

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

3822736

http://www.w3.org/2001/XMLSchema#string